However, recent evidence suggests that BCOR-related HG-ESS cells might variably express estrogen receptors, indicating that a combination of CDK4/6 inhibitors and aromatase inhibitors should be considered for ER-positive, BCOR-related metastatic HG-ESS patients [6]. This evidence concerns the gene CDK4 and endometrioid stromal sarcoma.